Table 1 Baseline characteristics of the 1194 CHC patients.
From: Evolution of ferritin levels in hepatitis C patients treated with antivirals
All (n = 1194) | Interferon-based therapy (n = 620) | DAA therapy (n = 355) | p values* | |
|---|---|---|---|---|
Male, n (%) | 627 (52.5) | 353 (56.9) | 166 (46.8) | 0.001 |
Age (years) | 56.93 ± 12.75 | 53.96 ± 11.72 | 60.33 ± 12.99 | < 0.001 |
BMI (kg/m2) | 24.80 ± 3.85 | 24.96 ± 3.76 | 24.80 ± 4.01 | 0.523 |
HCV genotype | ||||
Genotype 1, n (%) | 679 (56.9) | 327 (52.7) | 244 (63.1) | 0.001 |
Genotype 2, n (%) | 412 (34.5) | 247 (39.8) | 106 (29.9) | 0.001 |
Genotype 3, n (%) | 25 (2.1) | 16 (2.6) | 5 (1.4) | 0.16 |
Log HCV RNA (logIU/mL) | 6.00 ± 0.991 | 6.02 ± 1.05 | 6.03 ± 0.83 | 0.809 |
ALT (U/L) | 91.89 ± 96.59 | 96.92 ± 98.24 | 81.69 ± 89.55 | 0.016 |
eGFR (mL/min/1.73 m2) | 95.97 ± 38.40 | 102.73 ± 36.06 | 89.08 ± 39.86 | < 0.001 |
TG (mg/dL) | 103.54 ± 53.45 | 103.70 ± 52.77 | 103.97 ± 53.70 | 0.939 |
TC (mg/dL) | 170.30 ± 33.49 | 171.52 ± 31.60 | 170.58 ± 33.78 | 0.666 |
HOMA-IR | 3.23 ± 5.26 | 3.14 ± 4.45 | 3.24 ± 5.12 | 0.77 |
Uric acid (mg/dL) | 5.86 ± 1.59 | 5.94 ± 1.55 | 5.71 ± 1.62 | 0.041 |
Ferritin (ng/mL) | 386.0 ± 492.3 | 375.3 ± 434.1 | 381.7 ± 532.1 | 0.858 |
High ferritin, n (%) | 553 (46.3) | 296 (47.7) | 164 (46.2) | 0.853 |
Iron (μg/dL) | 132.5 ± 56.5 | 138.9 ± 55.3 | 136.3 ± 58.7 | 2.678 |
Fe/TIBC (%) | 0.404 ± 0.185 | 0.410 ± 0.181 | 0.40 ± 0.187 | 0.736 |
Hb (g/dL) | 13.92 ± 1.85 | 14.30 ± 1.65 | 13.69 ± 1.92 | < 0.001 |
NLR | 1.75 ± 0.96 | 1.63 ± 0.84 | 1.88 ± 1.03 | < 0.001 |
Platelet (103/μL) | 175.0 ± 66.3 | 176.9 ± 56.56 | 176.2 ± 72.2 | 0.884 |
Steatosis, n (%) | 630 (52.8) | 297 (47.9) | 204 (57.5) | 0.06 |
Liver cirrhosis, n (%) | 243 (20.4) | 136 (21.9) | 84 (23) | 0.38 |
FIB-4 index | 3.39 ± 3.39 | 3.09 ± 3.23 | 3.86 ± 3.64 | 0.003 |
IFNL3-rs12979860 CC genotype, n (%) | 1018 (85.3) | 533 (85.9) | 300 (84.5) | 0.371 |
